Key result
Low-dose aspirin therapy for cardiovascular prophylaxis demonstrates alarmingly poor adherence in clinical practice.
Observational
A large population-based study highlights alarmingly poor adherence to low-dose aspirin for cardiovascular prophylaxis in clinical practice.
Poor adherence may undermine aspirin's prophylactic benefit; leaves open optimal interventions to improve persistence.
Purpose: Cardiovascular (CV) diseases such as coronary heart disease, stroke, and peripheral arterial disease are the most prevalent cause of death in the United States, accounting for one out of three deaths (1). Low-dose acetylsalicylic acid (ASA) is the mainstay of CV risk management in high-risk populations. However, despite strong evidence supporting its use, community use of aspirin in CV prophylaxis remains suboptimal (2). Adherence with ASA therapy is of critical importance as poor adherence or discontinuation leads to an increased risk of major CV events. We report data from a large population-base study on compliance with low-dose ASA therapy in clinical practice.
No takes yet. Share an insight, caveat, or question.
Singh et al. (2013) conducted an observational in Cardiovascular disease. Low-dose acetylsalicylic acid (ASA) was evaluated on Compliance with low-dose ASA therapy. Low-dose aspirin therapy for cardiovascular prophylaxis demonstrates alarmingly poor adherence in clinical practice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: